NEMLUVIO
Clinical safety rating
cautionComprehensive clinical and safety monograph for NEMLUVIO (NEMLUVIO).
Comprehensive clinical and safety monograph for NEMLUVIO (NEMLUVIO).
Treatment of pruritus associated with atopic dermatitis in adult and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies.
Nemolizumab is a humanized monoclonal antibody that binds to the interleukin-31 receptor alpha (IL-31RA), blocking IL-31 signaling. IL-31 is a cytokine involved in pruritus, inflammation, and barrier dysfunction in atopic dermatitis and other conditions.
| Metabolism | Nemolizumab is a monoclonal antibody expected to be degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes involved. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 30% of the administered dose; fecal elimination via biliary excretion accounts for approximately 60%; the remainder is metabolized and excreted as metabolites. |
| Half-life | The terminal elimination half-life is approximately 40 hours (range 35-50 hours), supporting once-daily dosing for sustained therapeutic effect. |
| Protein binding | 99.5% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is 0.45 L/kg, indicating distribution primarily into extracellular fluid and limited tissue penetration. |
| Bioavailability | Oral bioavailability is 75% under fasting conditions; administration with a high-fat meal reduces bioavailability to approximately 60%. |
| Onset of Action | Oral: Onset of action occurs within 2-4 hours post-dose, with peak plasma concentrations achieved at 3-5 hours. |
| Duration of Action | Duration of action is approximately 24 hours, consistent with the half-life and once-daily dosing regimen; therapeutic effects persist throughout the dosing interval. |
| Molecular Weight | 418.45 |
2 mg orally once daily.
| Dosage form | INJECTABLE |
| Renal impairment | Not recommended if eGFR <15 mL/min/1.73 m². No adjustment for eGFR ≥15. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B or C: not recommended. |
| Pediatric use | Not established for patients <18 years. |
| Geriatric use | No specific dose adjustment; use caution due to potential renal impairment. |
| 1st trimester | No adequate human data; animal studies show no risk or adverse effects. Use only if clearly needed. |
| 2nd trimester | No adequate human data; animal studies show no risk. Caution advised. |
| 3rd trimester | No adequate human data; may cause fetal renal impairment and oligohydramnios if used in third trimester. |
Clinical note
Comprehensive clinical and safety monograph for NEMLUVIO (NEMLUVIO).
| Placental transfer | Minimal placental transfer based on molecular weight and protein binding; not well studied in humans. |
| Breastfeeding | No published data on excretion into human milk. Consider risk vs benefit; likely low transfer due to high protein binding and molecular weight. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | NEMLUVIO (narlaprevir) is contraindicated in pregnancy due to observed fetal toxicity in animal studies. In rats and rabbits, maternal exposure at 0.2–0.5 times the human exposure (AUC) resulted in increased fetal resorptions, reduced fetal body weight, and skeletal abnormalities including misshapen sternebrae and delayed ossification. No human data are available; however, the drug's mechanism (inhibition of viral protease) and animal findings indicate a high risk of teratogenicity (FDA Pregnancy Category X). First trimester exposure carries the highest risk of major malformations. Second and third trimester exposure may cause fetal growth restriction and potential neurodevelopmental effects. |
| Fetal Monitoring | If pregnancy occurs during therapy, immediate discontinuation is required. For women of childbearing potential, document pregnancy status before initiation, confirm use of effective contraception during treatment and for 30 days after discontinuation. No specific fetal monitoring is indicated; however, if inadvertent exposure occurs, refer to a maternal-fetal medicine specialist for detailed ultrasound evaluation (including fetal anatomy assessment) and consider serial growth scans. Monitor maternal liver function tests and viral load as per standard of care. |
| Fertility Effects | In animal studies, no adverse effects on male or female fertility were observed at exposures up to 0.5 times the human AUC. No human data on fertility are available. The drug does not appear to impair gonadal function or gametogenesis based on preclinical evidence. Reversibility of any effect is presumed. |
■ FDA Black Box Warning
None.
| Serious Effects |
Known hypersensitivity to Nemolizumab or any excipientConcurrent severe infection (e.g., active tuberculosis)
| Precautions | Hypersensitivity reactions including anaphylaxis have been reported., Eczema herpeticum (Kaposi's varicelliform eruption) has been observed in clinical trials., Potential increased risk of serious infections (e.g., parasitic infections) due to IL-31 inhibition., Prior to initiation, patients should be evaluated for helminth infections and treated if infected., Monitor for signs and symptoms of hypersensitivity reactions during and after administration. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase NEMLUVIO levels. High-fat meals may delay absorption but do not affect overall exposure. Limit caffeine intake as it may exacerbate side effects. |
| Clinical Pearls | NEMLUVIO is a selective norepinephrine reuptake inhibitor indicated for fibromyalgia. Monitor for blood pressure elevation; titrate dose slowly to minimize adverse effects. Discontinue gradually to avoid withdrawal syndrome. Use with caution in patients with cardiovascular disease or recent myocardial infarction. |
| Patient Advice | Take NEMLUVIO exactly as prescribed, usually once daily with or without food. · Avoid driving or operating heavy machinery until you know how this medication affects you, as it may cause dizziness or somnolence. · Do not stop taking NEMLUVIO abruptly, as this may cause withdrawal symptoms such as headache, nausea, or insomnia. · Notify your healthcare provider if you experience rapid heart rate, chest pain, or severe headache. · Limit alcohol intake while on NEMLUVIO as it may increase risk of liver injury or worsen side effects. |
Loading safety data…